Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 10 EVAX Evaxion receives Nasdaq notification over minimum stockholders’ equity requirement
May 10 EVAX Evaxion Receives Nasdaq Notification
May 10 ACLX Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
May 10 ALPN Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...
May 10 ALPN Alpine Immune ticks higher as HSR waiting period for Vertex Pharma deal expires
May 10 GNLX Genelux GAAP EPS of -$0.29 misses by $0.06
May 10 ACLX Arcellx GAAP EPS of -$0.14, revenue of $39.3M
May 10 ACLX Kite and Arcellx prepare to launch Phase III multiple myeloma trial
May 9 ALPN Alpine Immune Sciences GAAP EPS of -$0.28 beats by $0.12, revenue of $7.03M beats by $3.51M
May 9 ACLX Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset
May 9 ACLX Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
May 9 GNLX Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 9 ACLX Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9 ACLX Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9 ALPN Alpine Immune Sciences Reports First Quarter 2024 Financial Results
May 9 ACLX Arcellx Provides First Quarter 2024 Financial Results
May 9 CGON CG Oncology, Inc. reports Q1 results
May 9 CGON CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 7 ACLX Arcellx to Participate in Two Upcoming Investor Conferences
May 7 ALPN Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags